{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:59:44Z","timestamp":1792162784169,"version":"4.4.0"},"reference-count":141,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future.<\/jats:p>","DOI":"10.3390\/ijms26136518","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:58:23Z","timestamp":1751878703000},"page":"6518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0645-7020","authenticated-orcid":false,"given":"Krzysztof","family":"Drygalski","sequence":"first","affiliation":[{"name":"Department of Hypertension and Diabetology, Medical University of Gdansk, ul. Mariana Smoluchowskiego 17, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease\u2014Meta-analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/jamainternmed.2024.6431","article-title":"A Clinical Update on MASLD","volume":"185","author":"Zhang","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular Pathways of Nonalcoholic Fatty Liver Disease Development and Progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-Alcoholic Fatty Liver Disease: Pathophysiological Concepts and Treatment Options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0028-1091980","article-title":"Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease","volume":"28","author":"Malhi","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kasumov, T., Li, L., Li, M., Gulshan, K., Kirwan, J.P., Liu, X., Previs, S., Willard, B., Smith, J.D., and McCullough, A. (2015). Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126910"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular Mechanisms of Lipotoxicity and Glucotoxicity in Nonalcoholic Fatty Liver Disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jn\/138.8.1452","article-title":"Nonalcoholic Fatty Liver Disease in Humans Is Associated with Increased Plasma Endotoxin and Plasminogen Activator Inhibitor 1 Concentrations and with Fructose Intake","volume":"138","author":"Thuy","year":"2008","journal-title":"J. Nutr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal Microbiota Determines Development of Non-Alcoholic Fatty Liver Disease in Mice","volume":"62","author":"Llopis","year":"2013","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajt.2024.01.014","article-title":"OPTN\/SRTR 2022 Annual Data Report: Liver","volume":"24","author":"Kwong","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/clinem\/dgac624","article-title":"Approach to the Patient With Nonalcoholic Fatty Liver Disease","volume":"108","author":"Lomonaco","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-Term Persistence of Hormonal Adaptations to Weight Loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rajewski, P., Cie\u015bci\u0144ski, J., Rajewski, P., Suwa\u0142a, S., Rajewska, A., and Potasz, M. (2025). Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010217"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN Guideline on Clinical Nutrition in Liver Disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/17474124.2019.1634544","article-title":"Olive Oil Antioxidants and Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Abenavoli","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean Diet and Nonalcoholic Fatty Liver Disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/liv.14596","article-title":"High-protein Diet More Effectively Reduces Hepatic Fat than Low-protein Diet despite Lower Autophagy and FGF21 Levels","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Choi, Y.J., Jeon, S.-M., and Shin, S. (2020). Impact of a Ketogenic Diet on Metabolic Parameters in Patients with Obesity or Overweight and with or without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Nutrients, 12.","DOI":"10.3390\/nu12072005"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2478\/jtim-2020-0005","article-title":"Ketogenic, Hypocaloric Diet Improves Nonalcoholic Steatohepatitis","volume":"8","author":"Belopolsky","year":"2020","journal-title":"J. Transl. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with Intermittent Calorie Restriction or Low-Carb High-Fat Diet\u2013A Randomised Controlled Trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Johari, M.I., Yusoff, K., Haron, J., Nadarajan, C., Ibrahim, K.N., Wong, M.S., Hafidz, M.I.A., Chua, B.E., Hamid, N., and Arifin, W.N. (2019). A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-Day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-47763-8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.clnu.2017.11.018","article-title":"Effects of Alternate-Day Fasting or Daily Calorie Restriction on Body Composition, Fat Distribution, and Circulating Adipokines: Secondary Analysis of a Randomized Controlled Trial","volume":"37","author":"Trepanowski","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lavallee, C.M., Bruno, A., Ma, C., and Raman, M. (2022). The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. Nutrients, 14.","DOI":"10.3390\/nu14214655"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2147\/DMSO.S304357","article-title":"Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease","volume":"14","author":"Machado","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bae, J.C., Suh, S., Park, S.E., Rhee, E.J., Park, C.Y., Oh, K.W., Park, S.W., Kim, S.W., Hur, K.Y., and Kim, J.H. (2012). Regular Exercise Is Associated with a Reduction in the Risk of NAFLD and Decreased Liver Enzymes in Individuals with NAFLD Independent of Obesity in Korean Adults. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046819"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2015.07.010","article-title":"Relationship of Sitting Time and Physical Activity with Non-Alcoholic Fatty Liver Disease","volume":"63","author":"Ryu","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.14309\/ajg.0000000000000168","article-title":"Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort","volume":"114","author":"Byambasukh","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_41","first-page":"CD015033","article-title":"Vitamin E for People with Non-Alcoholic Fatty Liver Disease","volume":"2024","author":"Wen","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/jgh.16723","article-title":"Vitamin E Improves Serum Markers and Histology in Adults with Metabolic Dysfunction-associated Steatotic Liver Disease: Systematic Review and Meta-analysis","volume":"39","author":"Chee","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.1840040416","article-title":"Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane-Damaging Properties-Studies on Isolated Hepatocytes and Lipid Membrane Vesicles","volume":"4","author":"Becher","year":"1984","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xiang, Z., Chen, Y., Ma, K., Ye, Y., Zheng, L., Yang, Y., Li, Y., and Jin, X. (2013). The Role of Ursodeoxycholic Acid in Non-Alcoholic Steatohepatitis: A Systematic Review. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-140"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"ref_47","first-page":"1464","article-title":"Ursodeoxycholic Acid or Clofibrate in the Treatment of Non\u2013Alcohol\u2013Induced Steatohepatitis: A Pilot Study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"ref_48","first-page":"696","article-title":"Efficacy of Ursodeoxycholic Acid in Nonalcoholic Fatty Liver Disease: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"29","author":"Zhang","year":"2020","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC Inhibitor Alone or Co-Administered with a DGAT2 Inhibitor in Patients with Non-Alcoholic Fatty Liver Disease: Two Parallel, Placebo-Controlled, Randomized Phase 2a Trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sivakumar, P., Saul, M., Robinson, D., King, L.E., and Amin, N.B. (2024). SomaLogic Proteomics Reveals New Biomarkers and Provides Mechanistic, Clinical Insights into Acetyl CoA Carboxylase (ACC) Inhibition in Non-Alcoholic Steatohepatitis (NASH). Sci. Rep., 14.","DOI":"10.1038\/s41598-024-67843-8"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e056159","DOI":"10.1136\/bmjopen-2021-056159","article-title":"Efficacy and Safety of an Orally Administered DGAT2 Inhibitor Alone or Coadministered with a Liver-Targeted ACC Inhibitor in Adults with Non-Alcoholic Steatohepatitis (NASH): Rationale and Design of the Phase II, Dose-Ranging, Dose-Finding, Randomised, Placebo-Controlled MIRNA (Metabolic Interventions to Resolve NASH with Fibrosis) Study","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and Safety of PXL770, a Direct AMP Kinase Activator, for the Treatment of Non-Alcoholic Fatty Liver Disease (STAMP-NAFLD): A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical Trial: Pilot Study of Metformin for the Treatment of Non-alcoholic Steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Harrison, S.A., Alkhouri, N., Ortiz-Lasanta, G., Rudraraju, M., Tai, D., Wack, K., Shah, A., Besuyen, R., Steineger, H.H., and Fraser, D.A. (2025). A Phase IIb Randomised-Controlled Trial of the FFAR1\/FFAR4 Agonist Icosabutate in MASH. J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2025.01.032"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of Efruxifermin for Patients with Compensated NASH Cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","article-title":"Decreases in CT1 and Liver Fat Content Reflect Treatment-Induced Histological Improvements in MASH","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100392","DOI":"10.1016\/j.jhepr.2021.100392","article-title":"Pegbelfermin Selectively Reduces Secondary Bile Acid Concentrations in Patients with Non-Alcoholic Steatohepatitis","volume":"4","author":"Luo","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.70038","article-title":"Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH","volume":"61","author":"Raji","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and Metabolic Effects Associated with Weight Changes and Obeticholic Acid in Non-alcoholic Steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Non-Alcoholic Steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2022.10.027","article-title":"Changes in Abdominal Adipose Tissue Depots Assessed by MRI Correlate with Hepatic Histologic Improvement in Non-Alcoholic Steatohepatitis","volume":"78","author":"Shen","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and Renal Improvements with FXR Agonist Vonafexor in Individuals with Suspected Fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in Patients with NASH: A Phase II Double-Blind Placebo-Controlled Dose-Ranging Study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 Mg Once Weekly in Patients with Non-Alcoholic Steatohepatitis-Related Cirrhosis: A Randomised, Placebo-Controlled Phase 2 Trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/dom.16065","article-title":"Similar Weight Loss with Semaglutide Regardless of Diabetes and Cardiometabolic Risk Parameters in Individuals with Metabolic Dysfunction-associated Steatotic Liver Disease: Post Hoc Analysis of Three Randomised Controlled Trials","volume":"27","author":"Armstrong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/cid\/ciae384","article-title":"Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study","volume":"80","author":"Ditzenberger","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A Phase IIa Active-Comparator-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide in Patients with Non-Alcoholic Fatty Liver Disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-Agonist Cotadutide in Biopsy-Proven Noncirrhotic MASH With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of Ketohexokinase in Adults with NAFLD Reduces Liver Fat and Inflammatory Markers: A Randomized Phase 2 Trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Three-arm, Parallel-group Study to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics of PF-06835919 in Patients with Non-alcoholic Fatty Liver Disease and Type 2 Diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","article-title":"Safety and Efficacy of Once-Daily HU6 versus Placebo in People with Non-Alcoholic Fatty Liver Disease and High BMI: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"8","author":"Noureddin","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Without Cirrhosis","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065\u2013Deuterium-Stabilized (R)-Pioglitazone in Patients with NASH: A Phase II Randomized Placebo-Controlled Trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jimd.12510","article-title":"Therapeutic Potential of Deuterium-stabilized (R)-pioglitazone\u2014PXL065\u2014For X-linked Adrenoleukodystrophy","volume":"45","author":"Monternier","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The Pan-PPAR Agonist Lanifibranor Improves Cardiometabolic Health in Patients with Metabolic Dysfunction-Associated Steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Range, Proof-of-Concept, 24-Week Treatment Study of Lanifibranor in Adult Subjects with Non-Alcoholic Steatohepatitis: Design of the NATIVE Study","volume":"98","author":"Pierre","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Insulin Resistance and Hepatic Steatosis in Patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep4.1571","article-title":"LPCN 1144 Resolves NAFLD in Hypogonadal Males","volume":"4","author":"Albhaisi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100676","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting Acetyl-CoA Carboxylases for the Treatment of MASLD","volume":"65","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zalewska, A., Szarmach, I., \u017bendzian-Piotrowska, M., and Maciejczyk, M. (2020). The Effect of N-Acetylcysteine on Respiratory Enzymes, ADP\/ATP Ratio, Glutathione Metabolism, and Nitrosative Stress in the Salivary Gland Mitochondria of Insulin Resistant Rats. Nutrients, 12.","DOI":"10.3390\/nu12020458"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8831855","DOI":"10.1155\/2020\/8831855","article-title":"NAC Supplementation of Hyperglycemic Rats Prevents the Development of Insulin Resistance and Improves Antioxidant Status but Only Alleviates General and Salivary Gland Oxidative Stress","volume":"2020","author":"Zalewska","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13643-023-02238-w","article-title":"Efficacy and Safety of Carnitine Supplementation on NAFLD: A Systematic Review and Meta-Analysis","volume":"12","author":"Liu","year":"2023","journal-title":"Syst. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Savic, D., Hodson, L., Neubauer, S., and Pavlides, M. (2020). The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 12.","DOI":"10.3390\/nu12082178"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1111\/dom.16298","article-title":"Carnitine Supplementation Improves Insulin Sensitivity and Skeletal Muscle Acetylcarnitine Formation in Patients with Type 2 Diabetes","volume":"27","author":"Veeraiah","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/db21-0336","article-title":"Intermittent Leucine Deprivation Produces Long-Lasting Improvement in Insulin Sensitivity by Increasing Hepatic Gcn2 Expression","volume":"71","author":"Yin","year":"2022","journal-title":"Diabetes"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"De Bandt, J.-P., Coumoul, X., and Barouki, R. (2022). Branched-Chain Amino Acids and Insulin Resistance, from Protein Supply to Diet-Induced Obesity. Nutrients, 15.","DOI":"10.3390\/nu15010068"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Viollet, B. (2009). Targeting the AMPK Pathway for the Treatment of Type 2 Diabetes. Front. Biosci., 14.","DOI":"10.2741\/3460"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/10409238.2010.488215","article-title":"AMPK Inhibition in Health and Disease","volume":"45","author":"Viollet","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/apt.16602","article-title":"Review Article: Therapeutic Aspects of Bile Acid Signalling in the Gut-liver Axis","volume":"54","author":"Simbrunner","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in Steatohepatitis and Fibrosis in Mice","volume":"1","author":"Delgado","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.jhepr.2021.100237","article-title":"Aramchol Downregulates Stearoyl CoA-Desaturase 1 in Hepatic Stellate Cells to Attenuate Cellular Fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.3748\/wjg.v26.i34.5101","article-title":"Arachidyl Amido Cholanoic Acid Improves Liver Glucose and Lipid Homeostasis in Nonalcoholic Steatohepatitis via AMPK and MTOR Regulation","volume":"26","author":"Bilbao","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wang, W., Gao, X., Niu, W., Yin, J., and He, K. (2025). Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094077"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Aseem, S.O., Way, G., Wang, J., Zhao, D., Tai, Y., Gurley, E., Zeng, J., Wang, X., Hylemon, P.B., and Huebert, R.C. (2024). Aramchol Attenuates Fibrosis in Mouse Models of Biliary Fibrosis and Blocks the TGF\u03b2-Induced Fibroinflammatory Mediators in Cholangiocytes. bioRxiv, bioRxiv:2024.11.06.621880.","DOI":"10.1101\/2024.11.06.621880"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacl.2013.03.093","article-title":"The DGAT1 Inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans","volume":"7","author":"Meyers","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 Inhibitor Pradigastat on Triglyceride and ApoB48 Levels in Patients with Familial Chylomicronemia Syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"25474","DOI":"10.1074\/jbc.M202013200","article-title":"DGAT1 Is Not Essential for Intestinal Triacylglycerol Absorption or Chylomicron Synthesis","volume":"277","author":"Buhman","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"O\u2019Farrell, M., Duke, G., Crowley, R., Buckley, D., Martins, E.B., Bhattacharya, D., Friedman, S.L., and Kemble, G. (2022). FASN Inhibition Targets Multiple Drivers of NASH by Reducing Steatosis, Inflammation and Fibrosis in Preclinical Models. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-19459-z"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e161282","DOI":"10.1172\/jci.insight.161282","article-title":"Hepatic FASN Deficiency Differentially Affects Nonalcoholic Fatty Liver Disease and Diabetes in Mouse Obesity Models","volume":"8","author":"Matsukawa","year":"2023","journal-title":"JCI Insight"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kiepura, A., Stachyra, K., and Olszanecki, R. (2021). Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4). Biomedicines, 9.","DOI":"10.3390\/biomedicines9050467"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Szukiewicz, D. (2025). Potential Therapeutic Exploitation of G Protein-Coupled Receptor 120 (GPR120\/FFAR4) Signaling in Obesity-Related Metabolic Disorders. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202502.1303.v1"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nm.3014","article-title":"Autophagy Deficiency Leads to Protection from Obesity and Insulin Resistance by Inducing Fgf21 as a Mitokine","volume":"19","author":"Kim","year":"2013","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","article-title":"A Critical Role for ChREBP-Mediated FGF21 Secretion in Hepatic Fructose Metabolism","volume":"6","author":"Kim","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lee, H.A., and Kim, H.Y. (2023). Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119324"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like Peptide-1 Receptor-Based Therapeutics for Metabolic Liver Disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon Stimulates Gluconeogenesis by INSP3R1-Mediated Hepatic Lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/JOE-16-0649","article-title":"Glucagon-Induced Extracellular CAMP Regulates Hepatic Lipid Metabolism","volume":"234","author":"Lv","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic Inhibition of Ketohexokinase Prevents Fructose-Induced Metabolic Dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2023.02.010","article-title":"Ketohexokinase-C Regulates Global Protein Acetylation to Decrease Carnitine Palmitoyltransferase 1a-Mediated Fatty Acid Oxidation","volume":"79","author":"Helsley","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1021\/acs.jmedchem.0c00944","article-title":"Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose","volume":"63","author":"Futatsugi","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2018.11.002","article-title":"New Advances in Adaptive Thermogenesis: UCP1 and Beyond","volume":"29","author":"Chouchani","year":"2019","journal-title":"Cell Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing Mitochondrial Dysfunction in Cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.aaa0672","article-title":"Controlled-Release Mitochondrial Protonophore Reverses Diabetes and Steatohepatitis in Rats","volume":"347","author":"Perry","year":"2015","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Vlasova, K.Y., Ostroverkhov, P., Vedenyapina, D., Yakimova, T., Trusova, A., Lomakina, G.Y., Vodopyanov, S.S., Grin, M., Klyachko, N., and Chekhonin, V. (2022). Liposomal Form of 2,4-Dinitrophenol Lipophilic Derivatives as a Promising Therapeutic Agent for ATP Synthesis Inhibition. Nanomaterials, 12.","DOI":"10.3390\/nano12132162"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1053\/j.gastro.2014.08.038","article-title":"Extrahepatic Platelet-Derived Growth Factor-\u03b2, Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice","volume":"147","author":"Yoshida","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1038\/onc.2017.73","article-title":"Hepatic Cyclooxygenase-2 Overexpression Induced Spontaneous Hepatocellular Carcinoma Formation in Mice","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/gut.2008.157420","article-title":"Celecoxib Induces Hepatic Stellate Cell Apoptosis through Inhibition of Akt Activation and Suppresses Hepatic Fibrosis in Rats","volume":"58","author":"Paik","year":"2009","journal-title":"Gut"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 Is a Mediator and Potential Interventional Target for NASH and Subsequent Liver Cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 Inhibitors in Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus: A Systematic Review","volume":"10","author":"Raj","year":"2019","journal-title":"World J. Diabetes"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","article-title":"SGLT2 Inhibitors in Liver Patients","volume":"18","author":"Hsiang","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"789653","DOI":"10.1155\/2012\/789653","article-title":"Androgens and Adipose Tissue in Males: A Complex and Reciprocal Interplay","volume":"2012","author":"Mammi","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"272","DOI":"10.14310\/horm.2002.1356","article-title":"Steroid Hormones Interrelationships in the Metabolic Syndrome: An Introduction to the Ponderostat Hypothesis","volume":"11","author":"Alemany","year":"2012","journal-title":"Hormones"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"294278","DOI":"10.1155\/2015\/294278","article-title":"Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis","volume":"2015","author":"Shen","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2019.11.053","article-title":"Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men","volume":"19","author":"Sarkar","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_141","first-page":"60","article-title":"Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, \u03b2-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"Eur. Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:37Z","timestamp":1760033137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":141,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136518"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136518","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}